Cargando…
Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo
Anti-p17 antibodies are able to neutralize human immunodeficiency virus (HIV) entry in a mouse model. In this study, we identified a region of sequence similarity between the epitopes of anti-p17 neutralizing antibodies and anti-gp41 neutralizing 2F5 antibody and verified cross-reactivity between p1...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491952/ https://www.ncbi.nlm.nih.gov/pubmed/28713388 http://dx.doi.org/10.3389/fimmu.2017.00770 |
_version_ | 1783247225367822336 |
---|---|
author | Verrier, Bernard Paul, Stéphane Terrat, Céline Bastide, Liza Ensinas, Agathe Phelip, Capucine Chanut, Blandine Bulens-Grassigny, Laura Jospin, Fabienne Guillon, Christophe |
author_facet | Verrier, Bernard Paul, Stéphane Terrat, Céline Bastide, Liza Ensinas, Agathe Phelip, Capucine Chanut, Blandine Bulens-Grassigny, Laura Jospin, Fabienne Guillon, Christophe |
author_sort | Verrier, Bernard |
collection | PubMed |
description | Anti-p17 antibodies are able to neutralize human immunodeficiency virus (HIV) entry in a mouse model. In this study, we identified a region of sequence similarity between the epitopes of anti-p17 neutralizing antibodies and anti-gp41 neutralizing 2F5 antibody and verified cross-reactivity between p17 and 2F5 in vitro. The p17 sequence was modified to increase sequence identity between the p17 and 2F5 epitopes, which resulted in enhanced cross-reactivity in vitro. Immunogenicity of wild-type and modified p17 was characterized in a rabbit model. Both wild-type and mutated p17 induced anti-gp41 responses in rabbits; sera from these animals reacted with gp41 from different HIV clades. Moreover, introduction of the 2F5 sequence in p17 resulted in induction of antibodies with partially neutralizing activity. Based upon these data, we suggest that the natural cross-reactivity between HIV-1 p17 protein and 2F5 antibody can be exploited to induce antibodies with neutralizing activity in an animal model. |
format | Online Article Text |
id | pubmed-5491952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54919522017-07-14 Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo Verrier, Bernard Paul, Stéphane Terrat, Céline Bastide, Liza Ensinas, Agathe Phelip, Capucine Chanut, Blandine Bulens-Grassigny, Laura Jospin, Fabienne Guillon, Christophe Front Immunol Immunology Anti-p17 antibodies are able to neutralize human immunodeficiency virus (HIV) entry in a mouse model. In this study, we identified a region of sequence similarity between the epitopes of anti-p17 neutralizing antibodies and anti-gp41 neutralizing 2F5 antibody and verified cross-reactivity between p17 and 2F5 in vitro. The p17 sequence was modified to increase sequence identity between the p17 and 2F5 epitopes, which resulted in enhanced cross-reactivity in vitro. Immunogenicity of wild-type and modified p17 was characterized in a rabbit model. Both wild-type and mutated p17 induced anti-gp41 responses in rabbits; sera from these animals reacted with gp41 from different HIV clades. Moreover, introduction of the 2F5 sequence in p17 resulted in induction of antibodies with partially neutralizing activity. Based upon these data, we suggest that the natural cross-reactivity between HIV-1 p17 protein and 2F5 antibody can be exploited to induce antibodies with neutralizing activity in an animal model. Frontiers Media S.A. 2017-06-30 /pmc/articles/PMC5491952/ /pubmed/28713388 http://dx.doi.org/10.3389/fimmu.2017.00770 Text en Copyright © 2017 Verrier, Paul, Terrat, Bastide, Ensinas, Phelip, Chanut, Bulens-Grassigny, Jospin and Guillon. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Verrier, Bernard Paul, Stéphane Terrat, Céline Bastide, Liza Ensinas, Agathe Phelip, Capucine Chanut, Blandine Bulens-Grassigny, Laura Jospin, Fabienne Guillon, Christophe Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo |
title | Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo |
title_full | Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo |
title_fullStr | Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo |
title_full_unstemmed | Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo |
title_short | Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo |
title_sort | exploiting natural cross-reactivity between human immunodeficiency virus (hiv)-1 p17 protein and anti-gp41 2f5 antibody to induce hiv-1 neutralizing responses in vivo |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491952/ https://www.ncbi.nlm.nih.gov/pubmed/28713388 http://dx.doi.org/10.3389/fimmu.2017.00770 |
work_keys_str_mv | AT verrierbernard exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo AT paulstephane exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo AT terratceline exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo AT bastideliza exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo AT ensinasagathe exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo AT phelipcapucine exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo AT chanutblandine exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo AT bulensgrassignylaura exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo AT jospinfabienne exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo AT guillonchristophe exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo |